Publications of Patrick Ma, MD

Quantification of anaplastic lymphoma kinase protein expression in non-small cell lung cancer tissues from patients treated with crizotinib.
Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
Clin Chem. 2016;62(1):252-261.

Simpson's paradox - aggregating and partitioning populations in health disparities of lung cancer patients.
Fu P, Panneerselvam A, Clifford B, Dowlati A, Ma PC, Zeng G, Halmos B, Leidner R.
Stat Methods Med Res. 2015;24(6):937-948.

MET receptor juxtamembrane Exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
Ma PC.
Cancer Discov. 2015;5(8):802-805.


High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs RR, Ma PC.
J Thorac Oncol. 2014;9(5):646-653.

ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC, Lanigan CP, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR.
J Thorac Oncol. 2014;9(4):464-468.

RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Mukhopadhyay S, Pennell NA, Ali SM, Ross JS, Ma PC, Velcheti V.
J Thorac Oncol. 2014;9(11):1714-1719.

EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP, Tubbs RR, Minca EC, MacNamara S, Almeida FA, Ma PC, Pennell NA, Cicenia JC.
Lung Cancer. 2014;86(2):158-163.

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
Sharma N, Pennell NA, Nickolich M, Halmos B, Ma PC, Mekhail T, Fu P, Dowlati A.
Invest New Drugs. 2014;32(2):362-368.

Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.
Chi A, Ma PC, Fu G, Hobbs GR, Welsh JS, Nguyen NP, Jang SY, Dai J, Jin J, Komaki R.
PLoS One. 2013;8(4):e59729


Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC.
J Thorac Oncol. 2013;8(12):e109-e111.

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR.
J Mol Diagn. 2013;15(3):341-346.

Cancer genes in lung cancer: racial disparities: are there any?
El-Telbany A, Ma PC.
Genes Cancer. 2012;3(7-8):467-480.


MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y, Thiagarajan PS, Ma PC.
J Thorac Oncol. 2012;7(2):459-467.

Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC.
Cleve Clin J Med. 2012;79 Electronic Suppl 1:eS56-eS60.

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA, Yin L, Keshtgarpour M, Ma PC.
J Thorac Oncol. 2012;7(7):1200-1201.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, bdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.
Nat Genet. 2012;44(8):852-860.


MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, Vasanji A, Flask CA, Halmos B, Koon H, Ma PC.
Cancer Res. 2011;71(13):4494-4505.


Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.
Feng Y, Ma PC.
Cancer Discov. 2011;1(7):550-554.

ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
Bagai R, Fan W, Ma PC.
IDrugs. 2010;13(6):404-414.

Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays.
Wang J, Ramakrishnan R, Tang Z, Fan W, Kluge A, Dowlati A, Jones RC, Ma PC.
Clin Chem. 2010;56(4):623-632.

In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor.
Wu C, Tang Z, Fan W, Zhu W, Wang C, Somoza E, Owino N, Li R, Ma PC, Wang Y.
J Med Chem. 2010;53(1):139-146.

Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
Kluge A, Dabir S, Kern JA, Nethery D, Halmos B, Ma PC, Dowlati A.
Int J Cancer. 2009;125(7):1728-1734.


Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC.
Oncogene. 2009;28(4):518-533.


Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.
Cancer Res. 2007;67(21):10417-10427.